The genomic loss of PTEN/P53 activity, frequently seen in glioblastoma, removes these critical negative feedback points (including p21 activity), allowing EGR1 to act potentially without restraint on downstream target genes26. The gene discussed is EGR1; the disease is glioblastoma.